Dirk Bernicke

Learn More
PURPOSE VEGF-A blockade has been clinically validated as a treatment for human cancers. Angiopoietin-2 (Ang-2) expression has been shown to function as a key regulator of tumor angiogenesis and metastasis. EXPERIMENTAL DESIGN We have applied the recently developed CrossMab technology for the generation of a bispecific antibody recognizing VEGF-A with one(More)
The stilbene phytochemicals resveratrol and piceatannol have been reported to possess substantial antitumorigenic and antileukemic activities, respectively. Although recent experimental data revealed the proapoptotic potency of resveratrol, the molecular mechanisms underlying the antileukemic activity have not yet been studied in detail. In the present(More)
By non-covalent association after proteolytic cleavage, the pro-domains modulate the activities of the mature growth factor domains across the transforming growth factor-β family. In the case of bone morphogenic protein 9 (BMP9), however, the pro-domains do not inhibit the bioactivity of the growth factor, and the BMP9·pro-domain complexes have equivalent(More)
Purpose:VEGF-A blockade has been clinically validated as a treatment for human cancers. Angiopoietin2 (Ang-2) expression has been shown to function as a key regulator of tumor angiogenesis and metastasis. Experimental Design:We have applied the recently developed CrossMab technology for the generation of a bispecific antibody recognizing VEGF-A with one arm(More)
  • 1